Publications by authors named "M Bross"
Cyanobacteria are a diverse group of prokaryotic organisms that have been the subject of intense basic research, resulting in a wealth of knowledge about fundamental cellular processes such as photosynthesis. However, the translation of that research towards industry-relevant applications is still limited. To understand the reasons for this contradictory situation, we conducted a quantitative survey among researchers in the cyanobacterial community, a set of individual interviews with established researchers, and a literature analysis.
View Article and Find Full Text PDFIntroduction: We previously developed a Zr-labeled antibody-based immuno-positron emission tomography (immunoPET) tracer targeting interferon gamma (IFNγ), a cytokine produced predominantly by activated T and natural killer (NK) cells during pathogen clearance, anti-tumor immunity, and various inflammatory and autoimmune conditions. The current study investigated [Zr]Zr-DFO-anti-IFNγ PET as a method to monitor response to immune checkpoint inhibitors (ICIs).
Methods: BALB/c mice bearing CT26 colorectal tumors were treated with combined ICI (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1)).
Mental health issues among Ph.D. students are prevalent and on the rise, with multiple studies showing that Ph.
View Article and Find Full Text PDFArticle Synopsis
- Antitumor antibody therapies, like trastuzumab that targets HER2, have significantly improved cancer treatments but have variable effectiveness among patients.
- Researchers used genetically diverse mice models to explore how host genetics impact immune responses and treatment efficacy.
- The study found a specific genetic locus linked to positive therapy responses and highlighted differences in immune cell types, particularly macrophages, between effective and ineffective treatment responses.
Article Synopsis
- Immune checkpoint inhibitors (ICI) have improved cancer treatment, but many patients don’t benefit due to potential tumor and genetic factors.
- Researchers used Diversity Outbred (DO) and Collaborative Cross (CC) mouse models to study how host genetics affect ICI responses, identifying significant genetic regions linked to therapeutic outcomes.
- Notably, they discovered that prolactin, an immunomodulating cytokine, enhances ICI effectiveness, as indicated by increased tumor response and immune cell infiltration in mice treated with prolactin.